Article Figures & Data
Figures
- Figure 1 CONSORT Diagram
A total of 123 patients were identified as having transitioned from fingolimod to ocrelizumab or rituximab between 2010 and October 2020 at the UCSF Multiple Sclerosis and Neuroinflammation center; 108 were included in analyses. DMT = disease-modifying therapy; EMR = electronic medical record; UCSF = University of California, San Francisco
- Figure 2 Timing of the 10 (9 Shown) Clinical Relapses in the 12 Months Following Fingolimod Discontinuation
The vertical black line indicates the split between categorically long and short intervals between treatments (±30 days); red and blue coloring indicate the treatment status: between treatments (red) or after the first anti-CD20 infusion (blue). Data truncated at 500 days after fingolimod discontinuation.
- Figure 3 Clinical Relapses and MRI Activity in the Subset of 63 Patients With MRIs Available
Data presented on a timeline relative to anti-CD20 initiation. Green lines denote time off active treatment (interval), and red asterisks indicate clinical relapse. The end points denote available MRIs: blue-filled segment end points indicate Gd+ MRI, black-filled segment end points indicate the presence of new T2 lesions from prior comparison, and open end points denote MRIs unchanged from prefingolimod discontinuation reference image.
- Figure 4 ALCs in the Subset of 92 Patients With ALC Labs Checked, Relative to Fingolimod Discontinuation
Dots indicate ALC values available. Green dots indicate ALC in the normal range, defined as >0.8 × 10E9/L. Dots indicating ALC values below the normal range are gray before fingolimod discontinuation and red after fingolimod discontinuation. The vertical line indicates fingolimod discontinuation, and the horizontal gray lines represent the interval between fingolimod and anti-CD20 treatments. ALC = absolute lymphocyte count.
Tables
Letters: Rapid online correspondence
- Transitioning From S1P Receptor Modulators to B Cell–Depleting Therapies in Multiple Sclerosis Clinical, Radiographic, and Laboratory Data
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
